Printed From BioPortfolio.com

China's FDA Approves Gilead's Sovaldi to Treat Chronic HCV Infection

13:00 EDT 27 Sep 2017 | Drug Discovery Development

News

HCV is the fourth-most commonly reported infectious disease in China.

Contributed Author:

Gilead Sciences

Topics:

Drug Pipeline

Original Article: China's FDA Approves Gilead's Sovaldi to Treat Chronic HCV Infection

Give dad the gift of knowledge. Order his DNA Ancestry kit this Father's Day for $99 at 23andMe! Ord

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search

Relevant Topic

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...

News Quicklinks

Search Biotech, Medical and Healthcare News

Biotech News by Article Type

Biotech News by Location

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches

Topics

China's FDA Approves Gilead's Sovaldi to Treat Chronic HCV Infection

More From BioPortfolio on "China's FDA Approves Gilead's Sovaldi to Treat Chronic HCV Infection"

Relevant Topic

News Quicklinks